Aspirin Mouthwash in Treating Patients With Oral Leukoplakia
|ClinicalTrials.gov Identifier: NCT01238185|
Recruitment Status : Completed
First Posted : November 10, 2010
Last Update Posted : August 12, 2013
RATIONALE: Aspirin mouthwash may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of aspirin mouthwash in treating patients with oral leukoplakia.
|Condition or disease||Intervention/treatment||Phase|
|Precancerous Condition||Drug: acetylsalicylic acid Genetic: gene expression analysis Genetic: protein expression analysis Other: laboratory biomarker analysis Other: questionnaire administration Procedure: biopsy||Phase 1|
- To determine if oral topical acetylsalicylic acid mouthwash achieves modulation of COX-1, COX-2, and prostaglandin in oral dysplasia tissues in patients with oral leukoplakia.
- To determine if this drug achieves alteration of histopathology and gene and protein expression in tissue.
- To determine if this drug achieves aspirin-induced tissue changes relating to altered tumor biology.
- To assess local and general tolerability and safety of this drug in these patients.
OUTLINE: All patients undergo tissue biopsy for histological diagnosis. Patients without a histological diagnosis of precancerous oral dysplasia undergo routine follow-up. Patients with a histological diagnosis of precancerous oral dysplasia are sequentially allocated to 1 of 4 treatment groups.
- Group 1: Patients receive acetylsalicylic acid mouthwash (one 75 mg tablet dissolved in 250 mL of water) twice daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.
- Group 2: Patients receive acetylsalicylic acid mouthwash (two 75 mg tablets of acetylsalicylic acid dissolved in 250 mL of water) twice daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.
- Group 3: Patients receive acetylsalicylic acid mouthwash (one 300 mg tablet of acetylsalicylic acid dissolved in 250 mL of water) twice daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.
- Group 4: Patients receive acetylsalicylic acid mouthwash (one 300 mg tablet of acetylsalicylic acid dissolved in 250 mL of water) three times daily for 4-6 weeks, gargling for 60 seconds then expectorate it fully, before planned definitive surgical excision.
At the time of definitive surgical excision, the patient is asked to gargle with the last dose of acetylsalicylic acid mouthwash just before being anesthetized. A small biopsy of the dysplasia lesion is taken and examined for immediate effects of the acetylsalicylic acid mouthwash on the dysplasia lesion. The surgically excised tissue is treated in the same way as the initial biopsy tissue (i.e., half being used for routine histology to confirm the diagnosis and the other half for research purposes). Tissue samples are analyzed via enzyme immunosorbent assay, qRT-PCR, immunoblotting, ELISA, immunohistochemistry, gene array analysis, and microvessel density analysis.
Patients complete a questionnaire assessing local and general tolerability as well as adverse effects during the period of use of the mouthwash.
After completion of study treatment, patients are followed periodically.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Masking:||None (Open Label)|
|Official Title:||Oral Topical Cyclooxygenase Inhibitor (Aspirin) Mouthwash for Treatment of Oral Dysplasia|
|Study Start Date :||February 2010|
|Primary Completion Date :||October 2011|
|Study Completion Date :||October 2011|
- PGE2 levels as assessed by enzyme immunosorbent assay
- COX-1 and COX-2 mRNA as assessed by qRT-PCR
- COX-1 and COX-2 protein expression as assessed by immunohistochemistry and quantified by immunoblotting to determine whether COX inhibition in oral dysplasia tissues is actually possible by use of the mouthwash formulation
- Comparison of WHO histological grade and clinical size of dysplastic lesions before and after treatment and assessment of proliferating cell nuclear antigen
- Tolerability and possible oral and other adverse effects using a questionnaire
- VEGF mRNA expression as assessed by qRT-PCR
- Protein expression as assessed by ELISA and immunohistochemistry for VEGFA
- Global gene response of dysplastic tissue as assessed by Affymetrix gene expression microarrays
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01238185
|University of Birmingham|
|Birmingham, England, United Kingdom, B15 2TT|
|Institute of Head and Neck Studies and Education|
|Coventry, England, United Kingdom, CV2 2DX|
|Principal Investigator:||Hisham Mehanna, MD||Institute of Head and Neck Studies and Education, United Kingdom|